Melanoma Diagnosis
Melanoma Diagnosis
Melanoma is diagnosed by examining a suspicious lesion with a dermatoscope and then removing it for the pathologist to examine. The diagnosis is not made from the appearance alone, because the finding that governs treatment — how far the melanoma has grown into the skin — can only be measured on tissue. The assessment then moves to the lymph nodes for melanomas above the guideline thickness threshold, and to imaging when the risk of spread makes it worthwhile.
Examining the skin: what a dermatoscope adds
The assessment of a pigmented lesion is a comparison rather than a pattern match, and the instrument that makes it reliable is the dermatoscope — a magnifying device with a light that shows structures within the lesion:
- The examination is about the person, not only the lesion — a melanoma is often the lesion that looks different from the others, so the scalp, the soles, between the toes and the nails are all examined.
- Dermoscopic photography is used where several lesions need watching, so that the next comparison is against a recorded image rather than memory.
- A lesion that cannot be classified confidently is removed rather than observed — a few days of pathology settle a question that months of watching would not.
Removing the lesion: why the whole thing is taken
For a suspicious skin lesion the standard diagnostic procedure is an excisional biopsy — the whole lesion removed with a narrow margin of normal skin, usually two to three millimetres — because the pathologist must be able to see the deepest point and the surrounding skin:
- A shave or small punch can make the thickness unmeasurable — it may remove the superficial part and leave the deepest part behind, which is the measurement that decides treatment.
- A partial sample is used deliberately in specific sites — a large lesion, or one on the face or a digit, where an incisional biopsy or a full-thickness punch establishes the diagnosis before the definitive operation is planned.
- Under a nail the biopsy is of the matrix — the nail is lifted and the pigmented tissue sampled, which is why it is a small operation; damage to the nail afterwards is expected and preferable to a melanoma treated as an infection.
The pathology report: the measurements that decide the plan
The report written by the pathologist is the central document in melanoma, because it contains information no other test provides. These are the items that need to be there:
- Breslow thickness — the distance in millimetres from the top of the granular layer to the deepest melanoma cell; it sets the excision margin and the threshold for staging the nodes.
- Ulceration — whether the surface has broken down, recorded separately because it makes a melanoma behave less favourably than its thickness alone would predict.
- Mitotic rate — how many cells were seen dividing, which adds to the assessment particularly for thinner melanomas.
- Margins — whether the melanoma was removed completely, and how close it comes to the edge; an involved margin is why a further excision is planned.
- Microsatellites, lymphovascular and perineural invasion — small deposits beyond the lesion and involvement of vessels or nerves, all of which are additional unfavourable findings.
- Melanoma in situ is reported separately — the cells are confined to the epidermis, so there is no thickness to measure; it is treated by complete removal with a small margin.
Staging the lymph nodes: the sentinel node biopsy
One test answers directly whether the melanoma has reached the nodes that drain the area: the sentinel lymph node biopsy, in which a tracer and a dye identify the first draining node for the pathologist to examine in detail.
- It is offered by thickness rather than by preference — broadly for melanomas thicker than about 0.8 mm, and where ulceration or another unfavourable feature makes the risk worth measuring.
- It is usually done with the wider excision, so the conversation belongs before that operation is planned.
- A positive result changes the conversation, not the immediate operation — the options are removing the remaining nodes in that basin or close ultrasound surveillance, weighed against the risk of lymphoedema.
- Where a node is already enlarged and melanoma is confirmed in it, the operation becomes treatment rather than staging, and treatment after surgery is usually discussed at the same time.
Imaging: when it is needed, and what it is looking for
Imaging does not diagnose a melanoma of the skin — that is done with a dermatoscope and a biopsy. Its role is to look for spread, and it is used selectively, because for a thin melanoma the chance of finding anything is low:
- Ultrasound of the node basins examines the nodes that drain the site, guides a needle sample of an abnormal node, and is the method of surveillance where dissection is not chosen.
- CT and PET-CT survey the organs where melanoma most often appears, and are used for melanomas at higher risk of spread or where symptoms suggest it.
- MRI of the brain is used where spread to the brain is a concern, since the brain is a site melanoma reaches more often than most cancers.
- LDH in the blood is part of assessing advanced disease rather than a screening test, since the level reflects how much melanoma is present.
Tests on the tissue, and what is genuinely used to choose treatment
The melanoma tissue already in the laboratory is the source of the tests that decide whether targeted drug treatment is available, which means the answer rarely depends on another procedure:
- BRAF is the test that most often changes the plan — where it is present, a BRAF inhibitor combined with a MEK inhibitor becomes an option after surgery and for advanced disease.
- KIT is tested particularly in acral and mucosal melanomas, and NRAS is checked because it explains why some melanomas do not respond to BRAF-directed treatment.
- Melanoma that began inside the eye follows a different pathway, which is one reason uveal melanoma is managed with its own protocols.
- No blood test diagnoses melanoma or reliably detects recurrence, and genetic testing of the person is not part of choosing treatment outside specific family circumstances.
How the plan is put together
Melanoma is a disease in which a small number of findings decide a great deal, so the plan is built in a defined order rather than assembled from parallel opinions:
- The pathology comes first — thickness, ulceration, mitotic rate and margins decide the operation, and the node staging is discussed at the same time so that both are done together.
- The tissue markers come next, deciding whether a targeted option exists alongside the immune-based one; asking for them at the outset avoids the delay of obtaining them when a decision is urgent.
- The whole picture is reviewed at one meeting — pathology, surgery, medical and radiation oncology looking at the same material, with surveillance planned for years rather than months.